CJC-1295 (No DAC) Price Comparison — Compare 25 Vendors

View full research →
Growth hormone secretagogue researchBlendSafety Rating 7/10

Price Comparison

Compare vendors · per 5mg

25 vendors competing

VendorPrice$ / mgUpdated
Alpha Peptides8/10$25.57$28.41−10% · code PEPTIDEPRICES10$2.56Jun 12, 2026Buy →
Puratek Peptides9.5/10$40.46$44.95−10% · code PEPTIDEPRICES$4.05May 19, 2026Buy →
Hydro Research9/10$24.00$30.00−20% · code PEPTIDEP20$4.80Jun 5, 2026Buy →
Ascension Peptides8.5/10$25.00$50.00−50% · code peptidepri$5.00Apr 16, 2026Buy →
Ignite Peptides6.5/10$50.00$5.00Jun 12, 2026Buy →
Arizen Bio Labs6.5/10$53.99$59.99−10% · code PEPTIDEP10$5.40Jun 21, 2026Buy →

Research details

CJC-1295 — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeLimited clinical data; research protocols 100 mcg 1–3x dailysource ↗
AdministrationSubcutaneous injection
Half-life~30 minutes
Safety7/10 · Not FDA-approved
NCAA D1Banned

Overview

About CJC-1295

Mechanism of action

GHRH analogue; binds GHRH receptors on pituitary somatotrophs to stimulate pulsatile GH secretion. No DAC version has shorter action for more physiological GH pulses.

Safety profile

Water retention, numbness/tingling, insulin resistance (at high doses), fatigue, potential cortisol/prolactin increase. · Studied in human PK trials; well-tolerated; water retention, tingling reported; short-acting

Storage

Stability & handling

❄️Lyophilized (powder)−20°Cstable
💉Reconstituted2–8°Cwithin 14–30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Safety & Interactions

Contraindications & Drug Interactions

Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.

⚠ CriticalContraindication

Active malignancy — sustained GH/IGF-1 elevation is a theoretical tumor growth risk.

! CautionCaution

Type 2 diabetes or pre-diabetes — reduced insulin sensitivity reported with chronic GH agonism.

ℹ NoteInteraction

Ipamorelin / GHRP-2 / GHRP-6 — standard synergistic combo, amplifies GH pulses.

Blend

Component Compounds

CJC-1295 (No DAC)

AAs29MW~3,367 g/mol

GHRH receptor agonist · half-life 30 min–2 hrs

Ipamorelin

AAs5MW711.85 g/mol
Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Ghrelin receptor (GHSR-1a) agonist · no cortisol/prolactin elevation

Related pages

More on CJC-1295

Stack & Compare

Frequently Researched Together

Learn More

CJC-1295 Guide

CJC-1295 with DAC vs without DAC — the complete breakdown.

Read full guide · 9 min read →

Research

Studies & key findings

  • A GHRH analogue that extends the half-life of growth hormone-releasing hormone pulses, enabling once-daily or twice-weekly dosing versus native GHRH's minutes-long activity.
  • Paired with ipamorelin, CJC-1295 produces a robust, physiological GH pulse without blunting the normal GH feedback cycle.

6 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch